BRCA2 and neoplasm: Importantly, our in vivo studies indicate that while a-Egfl6 therapy improved response to a-PD-L1 therapy in both the 2F8c (s.c.)tumor model and the ID8p53–/– Brca2–/– (i.p.)model, it was more efficacious in the immune hot 2F8c tumor model.